08:59 AM EDT, 10/06/2026 (MT Newswires) -- Boule Diagnostics (BOUL.ST) updated its long-term licensing agreement with Q-Line Biotech covering diagnostic reagents, consumables and hematology analyzers in India, according to a Tuesday release. The updated deal is designed to simplify the commercial structure, align incentives for long-term growth, and create a stronger base for expanding the diagnostics company's installed systems across the country as the use of RFID technology increases.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.